Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

90.14USD
15 Nov 2018
Change (% chg)

$1.83 (+2.07%)
Prev Close
$88.31
Open
$87.63
Day's High
$90.29
Day's Low
$85.96
Volume
2,276,945
Avg. Vol
1,527,451
52-wk High
$125.84
52-wk Low
$77.50

Select another date:

Fri, Nov 2 2018

Photo

AbbVie sees hit to Humira sales from European competition

U.S. drugmaker AbbVie Inc on Friday lowered its forecast for overseas sales of its top-selling medicine, Humira, due to larger-than-expected pricing cuts because of new competition in Europe.

AbbVie sees hit to Humira sales from European competition

U.S. drugmaker AbbVie Inc on Friday lowered its forecast for overseas sales of its top-selling medicine, Humira, due to larger-than-expected pricing cuts because of new competition in Europe.

UPDATE 3-AbbVie sees hit to Humira sales from European competition

Nov 2 U.S. drugmaker AbbVie Inc on Friday lowered its forecast for overseas sales of its top-selling medicine, Humira, due to larger-than-expected pricing cuts because of new competition in Europe.

CORRECTED-UPDATE 2-AbbVie sees hit to Humira sales from European competition

Nov 2 U.S. drugmaker AbbVie Inc on Friday lowered its overseas sales forecast for its top-selling medicine, Humira, as it agreed to larger-than-expected price cuts due to new European competition.

Humira biosimilars available at up to 80 percent discount in Europe: AbbVie

AbbVie Inc said on Friday rival biosimilar versions of its best-selling drug Humira were available in Europe at discounts ranging from 10 percent to 80 percent.

Humira biosimilars available at up to 80 pct discount in Europe-AbbVie

Nov 2 AbbVie Inc said on Friday rival biosimilar versions of its best-selling drug Humira were available in Europe at discounts ranging from 10 percent to 80 percent.

AbbVie expects double-digit earnings growth in 2019

AbbVie Inc said on Friday it was confident that its earnings would grow in the double digits in 2019, in spite of the launch of biosimilar versions of its best-selling rheumatoid arthritis drug Humira in the European Union.

AbbVie expects double-digit earnings growth in 2019

Nov 2 AbbVie Inc said on Friday it was confident that its earnings would grow in the double digits in 2019, in spite of the launch of biosimilar versions of its best-selling rheumatoid arthritis drug Humira in the European Union.

AbbVie lifts profit target after cancer drug powers third-quarter beat

Nov 2 AbbVie Inc beat Wall Street estimates for third-quarter profit and raised its earnings forecast for the year on Friday, driven by strong sales of blockbuster cancer medicine Imbruvica.

AbbVie, Roche combo treatment meets main goal of leukemia trial

(This Oct 31 story corrects paragraph one to say targeted therapy, not immunotherapy)

Select another date: